Absci Corporation (Nasdaq: ABSI) priced an underwritten public offering of 13,495,277 shares of common stock at $7.41 per share, expecting to raise approximately $100 million in gross proceeds before underwriting discounts, commissions, and offering expenses, according to a press release.

The offering includes participation from Eli Lilly & Company alongside Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and an unnamed large investment management firm. All shares are being sold by Absci, and the offering was expected to close on or about June 25, 2026, subject to customary closing conditions.

Absci said it intends to use the net proceeds to advance ABS-201, its anti-PRLR antibody program targeting androgenetic alopecia and endometriosis, as well as for working capital and general corporate purposes.

Jefferies, J.P. Morgan, TD Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering. The shares are being offered under a shelf registration statement previously filed with the U.S. Securities and Exchange Commission.